IL13 and airway hyperresponsiveness: In addition, soluble IL-13Rα2 is effective in blocking the actions of IL-13, including IgE production, pulmonary eosinophilia and airway hyperresponsiveness in animal models of asthma [202] and humanised IL-13Rα2 is now entering phase I clinical trials in asthma [203].